Investing
Boston Scientific (BSX): Saving Itself Through Auctioning Off Pieces
Published:
Boston Scientific (BSX) did it shareholders a terrible disservice buy buying Guidant in a bidding war with Johnson & Johnson. It now has long-term debt of almost $8.3 billion. Troubles in its stent business have hurt earnings and the company lost money last quarter.
BSX shares which went from $13 five years ago to $44 in mid-2004, are back to $13. And, all of this is because management thought M&A would make the company bigger through cutting costs at an acquired company and relying on "synergy".
Well, it did not work, and now BSX has to auction off pieces of the company to save its skin and cover its debt service.
Boston Scientific has just sold its cardiac surgery and vascular surgery units off to Swedish company Getinge for $750 million in cash. These units went because, according to BSX, they were non-core assets.
When the going gets tough, all assets become "non-core".
Douglas A. McIntyre
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
